Texas Company Hatches Live Chicks from Artificial Eggs in Potential De-Extinction Breakthrough

On May 19, 2026, in a laboratory in Dallas, Texas, 26 baby chickens emerged from containers that bore little resemblance to eggs. They had developed inside 3D-printed titanium honeycomb structures lined with bioengineered silicone membranes — no biological shell involved [1][2]. Colossal Biosciences, the de-extinction startup behind the experiment, called it a landmark achievement and a critical step toward reviving birds that have been dead for centuries: the dodo and the South Island giant moa [1].

The announcement drew immediate international attention. It also drew immediate scientific skepticism. No peer-reviewed paper accompanied the claim. No hatch-rate data was disclosed. And the gap between incubating a chicken embryo in an artificial shell and reconstructing a species from fragmentary ancient DNA remains, by most independent assessments, enormous [3][4].

The Technology: What Colossal Actually Built

The artificial egg system works by transferring a chicken embryo, along with its yolk and albumen (egg white), into the titanium structure within 36 to 40 hours of the egg being laid [1]. The rigid outer shell houses a transparent silicone-based membrane engineered to replicate the gas-exchange function of a natural eggshell — allowing oxygen in and carbon dioxide out at rates that sustain embryonic respiration [2][5]. Calcium, which developing birds normally absorb from the inner surface of a biological shell, is added externally [1].

After roughly 18 days in a standard incubator, the chicks began pecking their way out [1]. Colossal described them as "healthy," though no further details on their condition, survival rates, or long-term health monitoring were provided in the press release [3].

The company frames the platform as size-scalable. Versions for emu and ostrich embryos are under development [1]. This matters because the South Island giant moa laid eggs estimated at roughly 80 times the volume of a chicken egg and eight times that of an emu egg [1]. If the system cannot support embryos of that scale, it cannot serve its stated purpose.

What Scientists Say — and What They Can't Yet Evaluate

The reaction from independent researchers has been a mix of genuine interest and frustration at the absence of data.

Neil Gostling, a paleobiologist at the University of Southampton, called the work "brilliant" and "remarkable" [1]. But Paul Mozdziak, a biologist at North Carolina State University, was more cautious: "Without data, it's really impossible to judge what the true impact is" [1].

Mike McGrew, an embryology professor at the University of Edinburgh who has worked extensively with avian embryo culture, noted that previous artificial casing systems have shown "low, unpredictable hatching rates" and said he would find value in the work only if Colossal's rates significantly exceed existing methods [4]. Colossal has not disclosed how many embryos were transferred, how many failed, or what percentage hatched — making that comparison impossible [3].

Chris Elphick, an ornithologist at the University of Connecticut, questioned the practical value, noting that the process essentially transfers natural egg contents into an artificial shell, offering no advantage over keeping embryos in natural eggs for existing species [4].

The company has stated it does not plan to publish a peer-reviewed paper on the artificial egg results [1]. Independent scientists have not evaluated the methodology [3][4].

The De-Extinction Roadmap: From Chickens to Dodos

Colossal's ambitions extend well beyond chickens. Founded in 2021 by entrepreneur Ben Lamm and Harvard geneticist George Church, the company has active programs targeting the woolly mammoth, the thylacine (Tasmanian tiger), and — most relevant to the artificial egg — the dodo and the South Island giant moa [6][7].

The dodo (Raphus cucullatus), a flightless bird endemic to Mauritius, went extinct in the late 17th century. The moa, a genus of enormous flightless birds native to New Zealand, disappeared around 600 years ago. Neither species left behind intact DNA. What scientists have recovered consists of mitochondrial DNA and highly fragmentary nuclear DNA extracted from preserved remains [8].

Colossal's approach involves editing the genome of the Nicobar pigeon — the dodo's closest living relative — using CRISPR to introduce dodo-associated genetic traits, then using primordial germ cells (PGCs) to develop chimeric embryos [6]. In 2025, the company announced it had successfully cultured pigeon PGCs for the first time, a step it called critical to the program [6]. A flock of gene-edited chickens has been established as potential surrogates [6].

But Victoria Herridge, an evolutionary biologist at the University of Sheffield, argues this framing is misleading. "Nothing will ever bring back a mammoth; nothing will ever bring back a dodo. Extinction really is forever," she told Scientific American [4]. What the technology produces, she said, are "novel organisms, something completely new" — not faithful replicas of extinct species [4]. The IUCN itself, in its 2016 guidelines on de-extinction, defined the goal as creating "proxies" that are "functionally equivalent" to extinct species, not genetic duplicates [9].

A $10 Billion Company With an Expanding Portfolio

Colossal's financial trajectory has been steep. Since its founding, it has raised over $555 million, including a $320 million Series C round in September 2025 led by TWG Global, with participation from USIT, Bob Nelsen of ARCH Venture Partners, and filmmaker Peter Jackson, who committed $15 million specifically to the moa project [6][10]. The company's valuation reached $10.32 billion, making it Texas's first "decacorn" [10].

Source: Crunchbase / Company Announcements

Data as of May 19, 2026CSV

The business model extends beyond conservation. Colossal is exploring commercial spin-outs in human healthcare, plastic degradation, and computational biology [10]. Its genetic engineering platform and CRISPR expertise have applications across agriculture, pharmaceuticals, and industrial biotech. Whether the company's long-term revenue depends on successfully producing a living dodo or on licensing the underlying technology is an open question — and one that matters for evaluating how its scientific claims should be weighed.

The Opportunity Cost: 42,000 Species Can't Wait

Critics of de-extinction frame the issue in stark economic terms. A 2015 study estimated that saving an endangered or critically endangered species costs a mean of $1.55 million — roughly $2.1 million adjusted for inflation [9]. By that math, the $555 million raised by Colossal could theoretically fund protection for hundreds of threatened species [9].

The IUCN Red List currently classifies over 9,700 species as critically endangered, more than 16,000 as endangered, and over 16,000 as vulnerable [11].

Source: IUCN Red List

Data as of Dec 1, 2024CSV

Michael Parr, president of the American Bird Conservancy, has pointed out that existing captive breeding programs succeed without artificial eggs, and that the larger unsolved obstacles are habitat loss and reintroduction logistics [4]. Nic Rawlence, an evolutionary geneticist at the University of Otago, has argued that the technology would be better applied to critically endangered living birds like the kākāpō than to species that have been extinct for centuries [4].

Proponents counter that Colossal's work generates tools — PGC culture, genome editing, artificial incubation — that can serve both de-extinction and conservation of living species. The company has also formed a Mauritius Dodo Advisory Committee and says it is developing a rewilding program in consultation with local experts [6].

Legal and Regulatory Vacuum

If a dodo proxy were produced tomorrow, no existing legal framework would clearly govern its status. The U.S. Endangered Species Act protects species listed as threatened or endangered — but the dodo, being extinct, is not on the list [12]. CITES regulates international trade in over 40,900 species [12], but its provisions address wild populations and their derivatives, not lab-created organisms assembled from edited pigeon genomes.

A 2025 analysis published in a review of de-extinction ethics noted that European legal frameworks are "ineffective in addressing these emerging biotechnologies" [13]. The situation in the United States is similarly ambiguous. The USDA regulates genetically modified organisms in agriculture, and the FDA has authority over gene-edited animals intended for food or therapeutic use, but a gene-edited pigeon proxy designed for rewilding on a foreign island fits neatly into none of these categories.

The question of jurisdiction becomes more complex internationally. Mauritius would presumably have a say in whether a dodo proxy could be released on its territory. New Zealand's relationship with the moa project involves indigenous Māori stakeholders through Colossal's partnership with the Ngāi Tahu Research Centre [10]. No international treaty currently addresses the creation, transport, or release of organisms representing extinct species.

Ecological Risks of Reintroduction

Even if the biological and legal hurdles are cleared, reintroducing a dodo-like organism to Mauritius raises ecological questions that have no easy answers. The island's ecosystem has changed fundamentally since the 1600s. Invasive species — rats, pigs, macaques — that contributed to the dodo's extinction remain present and continue to damage native flora and fauna [14][15].

Research published in 2023 found that introduced species such as macaques are more likely to break open seeds than disperse them, and that seed predation on Mauritius has increased by more than half since the time of the dodo [15]. A dodo proxy released into this environment would face predation pressure from species it never co-evolved with, in a habitat where many of the plants it once fed on have themselves become rare or extinct [14].

There are cautionary precedents. Reintroduction biology has documented cases where species released into altered ecosystems became ecological disruptors themselves, or simply failed to establish viable populations [14]. The dodo's ecological role — as a large frugivore and seed disperser — is understood only in broad terms, and reconstructing its behavior from bone morphology and limited historical accounts involves significant inference [15].

How This Fits the Broader Colossal Timeline

The artificial egg announcement is the latest in a series of headline-generating milestones from Colossal. In April 2025, the company announced the birth of three "dire wolf" pups — Romulus, Remus, and Khaleesi — created by editing 20 genetic variants in 14 genes of modern grey wolves [7]. The company called it the first de-extinction of an animal, though critics noted the animals were modified wolves, not true dire wolves, which diverged from grey wolves roughly 5.7 million years ago [7].

The woolly mammoth program aims to produce hybrid calves by 2028, using edited Asian elephant cells [7][16]. The thylacine project announced a 99.9% accurate genome reconstruction in late 2024 and has developed an artificial uterus prototype for marsupial embryos [7].

Each announcement has followed a similar pattern: a press release with striking claims, significant media coverage, and limited independent scientific verification. NPR reported in March 2026 that the company "breeds controversy" alongside its organisms [16].

Source: OpenAlex

Data as of Jan 1, 2026CSV

Academic publication on de-extinction has grown substantially over the past decade, peaking at over 44,000 papers in 2023 before declining, suggesting the field is maturing but also that initial enthusiasm may be moderating as practical challenges become clearer.

Animal Welfare: The Unspoken Variable

One dimension largely absent from Colossal's announcements is the welfare cost of the work. The company has not disclosed how many embryos were created and discarded to achieve 26 successful hatchings [3]. In somatic cell nuclear transfer (SCNT) — the cloning technique used in some de-extinction approaches — mammalian species consistently show low efficiency, with frequent embryonic failure, pregnancy loss, and postnatal abnormalities [13].

For avian embryos, the welfare calculus is different but not absent. Transferring embryos to artificial shells and adding calcium manually introduces variables that natural incubation handles automatically. Each failed embryo represents an animal that began developing and did not survive. Whether existing institutional animal care and use committee (IACUC) frameworks adequately cover embryos of gene-edited or chimeric species — organisms that don't fit neatly into existing taxonomies — is a question that regulatory bodies have not yet answered [13].

The 2025 review in Reviving the Dire Wolf? noted that de-extincted animals face "long-term welfare risks" and that current legal frameworks provide inadequate protections [13].

What to Watch For

The artificial egg is a genuine engineering achievement — growing a chicken embryo to hatching outside a biological shell is not trivial. But the distance between that achievement and producing a living representative of an extinct species involves challenges that are biological, ecological, legal, and ethical, each of which remains substantially unresolved.

The key indicators to watch: whether Colossal publishes peer-reviewed data on hatch rates and embryo viability; whether the system scales to emu- and ostrich-sized embryos; whether pigeon PGC editing produces viable chimeric embryos carrying dodo-associated traits; and whether any regulatory body steps forward to establish jurisdiction over lab-created organisms of extinct species.

Until then, 26 healthy chickens in a Dallas lab remain exactly what they are — chickens, hatched from a novel container, carrying the weight of a $10 billion narrative about reversing extinction.